Quantum-Si reported a revenue of $552,000 for the third quarter of 2025, a decrease from the prior year. The company experienced a net loss of $35.7 million, significantly higher than the previous year, primarily due to one-time charges for legacy litigation settlements and lease termination expenses. Despite the financial losses, Quantum-Si made progress on its Proteus development program and expanded its instrument placement program to academic customers.

Quantum-Si achieved 84% YoY revenue growth in Q1 2025 with the successful launch of Platinum Pro units and ongoing investment in proteomics R&D. Operating expenses increased modestly as the company maintained focus on commercialization and product development.

Quantum-Si achieved a milestone in Q4 2024 with revenue reaching $1.2 million, a substantial increase from the previous year. The company recorded a net loss of $33.1 million, reflecting higher operating expenses as commercialization efforts ramped up. Gross profit was $0.6 million, with a gross margin of 51%. The company also raised over $86 million in capital to extend its cash runway into the second half of 2027.

Quantum-Si reported revenue of $787,000 for the third quarter of 2024. The company is focusing on commercial execution and innovation, with new kits on track for launch in Q4. They anticipate not achieving their full year guided revenue range of $3.7 million to $4.2 million.

Quantum-Si reported revenue of $622,000 in the second quarter of 2024. The company launched the version 3 sequencing kit, completed the first quarter of full commercial launch of the Platinum® instrument, and appointed Chuck Kummeth as independent Chairman of the Board of Directors.

Quantum-Si reported revenue of $457,000 for the first quarter of 2024 and commenced the full commercial launch of its Platinum instrument. The company reaffirmed its full year 2024 financial guidance and expects to launch version 3 of its sequencing kit by the end of Q3 2024.

Quantum-Si reported a revenue of $400,000 for Q4 2023 as they continued the controlled commercial launch of their Platinum instrument. The company's gross margin was 45%. They are finalizing commercial readiness and expect full commercial launch by the end of Q1 2024. The net loss decreased to $22.0 million, and total operating expenses decreased to $28.1 million.

Quantum-Si reported revenue of $223,000 during its controlled commercial launch of the Platinum instrument in Q3 2023. The company completed a strategic review of R&D and made organizational changes to focus on delivering capabilities and applications with the highest customer demand. They anticipate transitioning to a full commercial launch in early 2024.

Quantum-Si Incorporated reported financial results for the second quarter ended June 30, 2023. The company recorded revenue of $205,000, a gross profit of $78,000, and a gross margin of 38.0%. Operating expenses were $27.0 million, and the net loss was $25.6 million. Adjusted EBITDA was negative $22.9 million. Cash and cash equivalents and investments in marketable securities were $297.2 million as of June 30, 2023.

Quantum-Si Incorporated reported first quarter 2023 financial results, with revenue of $254,000 and a gross margin of 48.8%. The company's business funnel is robust and they are well-positioned to accelerate commercial momentum in the second half of the year. They expect non-GAAP operating expense growth to be approximately flat in 2023 relative to the prior year.

Quantum-Si Incorporated reported a net loss of $33.14 million for the fourth quarter of 2022. The company launched Platinum, its benchtop protein sequencer, and executed multiple industry collaborations. They expect cash runway into 2026.

Quantum-Si's net loss was $31.7 million, and adjusted EBITDA was negative $22.9 million. The company is preparing to launch its Platinum instrument and expects to begin shipments in Q1 2023.

Quantum-Si reported a net loss of $32.4 million and an adjusted EBITDA of negative $25.8 million for the second quarter of 2022. The company held $400.7 million in cash and cash equivalents and investments in marketable securities as of June 30, 2022.

Quantum-Si's operating expenses increased by 130% compared to the previous year. The company's net loss was $35.2 million, and adjusted EBITDA was negative $27.4 million. They held $434.8 million in cash, cash equivalents and marketable securities as of March 31, 2022.

Quantum-Si reported increased operating expenses due to expansion of the Early Access program, application ecosystem creation, new facility operations, and acquisition of Majelac Technologies LLC. Net loss was $18.1 million and adjusted EBITDA was negative $17.5 million. The company had $500.2 million in cash and cash equivalents and marketable securities as of September 30, 2021.